User login
Key clinical point: Achievement of low or minimal disease activity levels with guselkumab therapy diminished radiographic progression over 2 years in patients with psoriatic arthritis (PsA) at risk for radiographic damage.
Major finding: Among patients receiving guselkumab, the mean change in total van der Heijde-Sharp score from 0 to 100 weeks was numerically lower among those who achieved clinical response at week 52 vs non-responders, as assessed by ≥20% improvement in American College of Rheumatology criteria (1.0-1.2 vs 2.8-4.1), PsA Disease Activity Score low disease activity (LDA; 1.0 vs 1.9-2.4), and Disease Activity in PsA LDA (0.7-0.9 vs 2.3-3.1).
Study details: The data come from a post hoc analysis of the DISCOVER-2 study including 664 biologic-naïve patients with PsA who received guselkumab or placebo.
Disclosures: This study was funded by the Janssen Research & Development, LLC. Some authors reported ties with various sources, including Janssen. Some authors declared being employees of Janssen and owning stocks in Johnson & Johnson.
Source: Gottlieb AB et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: Results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open. 2023;9:e002789 (Feb 24). Doi: 10.1136/rmdopen-2022-002789
Key clinical point: Achievement of low or minimal disease activity levels with guselkumab therapy diminished radiographic progression over 2 years in patients with psoriatic arthritis (PsA) at risk for radiographic damage.
Major finding: Among patients receiving guselkumab, the mean change in total van der Heijde-Sharp score from 0 to 100 weeks was numerically lower among those who achieved clinical response at week 52 vs non-responders, as assessed by ≥20% improvement in American College of Rheumatology criteria (1.0-1.2 vs 2.8-4.1), PsA Disease Activity Score low disease activity (LDA; 1.0 vs 1.9-2.4), and Disease Activity in PsA LDA (0.7-0.9 vs 2.3-3.1).
Study details: The data come from a post hoc analysis of the DISCOVER-2 study including 664 biologic-naïve patients with PsA who received guselkumab or placebo.
Disclosures: This study was funded by the Janssen Research & Development, LLC. Some authors reported ties with various sources, including Janssen. Some authors declared being employees of Janssen and owning stocks in Johnson & Johnson.
Source: Gottlieb AB et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: Results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open. 2023;9:e002789 (Feb 24). Doi: 10.1136/rmdopen-2022-002789
Key clinical point: Achievement of low or minimal disease activity levels with guselkumab therapy diminished radiographic progression over 2 years in patients with psoriatic arthritis (PsA) at risk for radiographic damage.
Major finding: Among patients receiving guselkumab, the mean change in total van der Heijde-Sharp score from 0 to 100 weeks was numerically lower among those who achieved clinical response at week 52 vs non-responders, as assessed by ≥20% improvement in American College of Rheumatology criteria (1.0-1.2 vs 2.8-4.1), PsA Disease Activity Score low disease activity (LDA; 1.0 vs 1.9-2.4), and Disease Activity in PsA LDA (0.7-0.9 vs 2.3-3.1).
Study details: The data come from a post hoc analysis of the DISCOVER-2 study including 664 biologic-naïve patients with PsA who received guselkumab or placebo.
Disclosures: This study was funded by the Janssen Research & Development, LLC. Some authors reported ties with various sources, including Janssen. Some authors declared being employees of Janssen and owning stocks in Johnson & Johnson.
Source: Gottlieb AB et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: Results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open. 2023;9:e002789 (Feb 24). Doi: 10.1136/rmdopen-2022-002789